Rachel McConachie, RN, BSN, Dignity Health Cancer Institute of Greater Sacramento, discusses how her cancer center has adapted to providing patients with telemedicine-driven genetic counseling.
Pek Lum, PhD, discusses an AI-driven pharmaceutical company's efforts of mitigating cancer therapy toxicities through an AI engine.
Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.
Laura Chow, MD, FRCPC, discusses the clinical significance of the ASCEND-7 trial, which examined the intracranial effects of ceritinib in ALK-positive NSCLC.
Jeffrey Rubnitz, MD, PhD, discusses a study on the safety and activity of venetoclax plus chemo for young patients with heavily relapsed/refractory AML.
Nikolai Podoltsev, MD, PhD, discusses the underuse of phlebotomy and hydroxyurea in older patients with PV.
Xue-Zhong Yu, MD, MS, MBA, discusses Sirtuin-1 as a possible therapeutic target for the control of GVHD.
Stay in the know.
OncNet Newsletter